watch
Gilead Sciences, Inc.

Gilead Sciences, Inc.

Sector: Biological Products Except Diagnostic Substances Region: CA, United States


: | Nasdaq: GILD | XETRA: GIS


Similar to: ALLENEX AB, BioTime, Inc., NPS Pharmaceuticals, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus/AIDS, liver diseases such as hepatitis B virus and hepatitis C virus, serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

S&P Capital IQ Focus Stock of the Week: Gilead Sciences Inc.

S&P Capital IQ Equity Analyst Steve Silver has a 5-STARS "Strong Buy" recommendation for Gilead Sciences Inc. For more information, please visit: www.marketscope.com. Follow us on Twitter @spmarketscope for more Trends & Ideas, ranking changes, and investment strategies.

Gilead Sciences, Inc. video

S&P Capital IQ Focus Stock of the Week: Gilead Sciences Inc.

Gilead Sciences, Inc. video

Gilead Sciences Entered Into A License Agreement With Tibotec Pharmaceuticals

Gilead Sciences, Inc. video

Gilead Sciences CEO John Martin, Ph.D., on HIV Treatment Innovation & Healthcare Reform

Executives

John C. Martin, PhD, Chairman and Chief Executive Officer
Dr. Martin joined Gilead Sciences in 1990 and currently serves as Chairman of the Board of Directors and Chief Executive Officer. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.
Dr. Martin is a member of the Board of Directors of the California Healthcare Institute and Gen-Probe Incorporated. He also serves on the University of Southern California Board of Trustees.
Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute. He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
John F. Milligan, PhD, President and Chief Operating Officer
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
Robin L. Washington, Senior Vice President and Chief Financial Officer
Ms. Washington joined Gilead as Senior Vice President and Chief Financial Officer in May 2008. In this role, she oversees Gilead's worldwide Finance and Investor Relations functions. Prior to joining Gilead, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role of Senior Vice President and Corporate Controller. She previously was a Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago and a Senior Auditor for Deloitte & Touche.
Ms. Washington holds a bachelor's degree in business administration from the University of Michigan and a MBA from Pepperdine University. She currently serves on the Board of Directors of MIPS Technologies, Inc. and the Children’s Discovery Museum of San Jose.

News & Analysis

You may also be interested in: